Johnson & Johnson Family of Companies
NEWS
Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.
Johnson & Johnson is hoping its $100 million deal with Theravance will serve as a replacement for Remicade which lost patent protection.
Life sciences giant Johnson & Johnson may be shopping around its sterilization products division.
Janssen got a little love from the FDA on Wednesday.
Syndesi will work to modulate the synaptic vesicle protein SV2A.
The June 30, 2017 lawsuit asserts that the EndoWrist violates seven Ethicon patents.
J&J inked a global collaboration deal with Theravance Biopharma to develop a drug for IBD.
The companies were evaluated extensively on Career Pages, Job Boards, Employee Reviews & Candidate Engagement, Accolades, Recruitment Marketing, and Social Responsibility.
The U.S. Patent & Trademark Office is paving the way for generic challengers to J&J’s prostate cancer drug Zytiga.
JOBS
IN THE PRESS